Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BACE1 | P56817 | 1/20 | 0.51 |
| ▸ | CA12 | O43570 | 2/20 | 0.50 |
| ▸ | CA1 | P00915 | 2/20 | 0.50 |
| ▸ | CA2 | P00918 | 2/20 | 0.50 |
| ▸ | CA9 | Q16790 | 2/20 | 0.50 |
| ▸ | PLAU | P00749 | 1/20 | 0.49 |
| ▸ | LMNA | P02545 | 1/20 | 0.48 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.48 |
| ▸ | TSHR | P16473 | 1/20 | 0.47 |
| ▸ | TP53 | P04637 | 1/20 | 0.46 |
| ▸ | MAPT | P10636 | 1/20 | 0.46 |
| ▸ | NPC1 | O15118 | 1/20 | 0.46 |
| ▸ | RAB9A | P51151 | 1/20 | 0.46 |
| ▸ | POLB | P06746 | 1/20 | 0.46 |
| ▸ | HTT | P42858 | 1/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.45 |
| ▸ | MIF | P14174 | 1/20 | 0.45 |
| ▸ | ATM | Q13315 | 1/20 | 0.44 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.44 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13521671 | 1.00 | BACE1 (0.51) | BACE1CA12CA1CA2CA9 | |
| SCHEMBL12294698 | 1.00 | BACE1 (0.51) | BACE1CA12CA1CA2CA9 | |
| SCHEMBL5097623 | 0.84 | LMNA (0.50) | CA12CA1CA2CA9LMNA | |
| SCHEMBL6376097 | 0.84 | PLAU (0.45) | CA12CA1CA2CA9PLAU | |
| SCHEMBL6375277 | 0.83 | ALDH1A1 (0.50) | CA12CA1CA2CA9PLAU | |
| SCHEMBL8444209 | 0.82 | LMNA (0.46) | CA12CA1CA2CA9PLAU | |
| SCHEMBL12295603 | 0.82 | PLAU (0.47) | BACE1CA12CA1CA2CA9 | |
| SCHEMBL8811364 | 0.82 | LMNA (0.48) | CA12CA1CA2CA9PLAU | |
| SCHEMBL15184648 | 0.82 | ALDH1A1 (0.53) | BACE1CA12CA1CA2CA9 | |
| SCHEMBL8363864 | 0.82 | ALDH1A1 (0.53) | BACE1CA12CA1CA2CA9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 35 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-0435059-B1 | Retroviral protease inhibitors | HOECHST AG (DE) | 1997-11-05 | — | — | EP | claimed |
| US-5663139-A | VIRICIDE OLIGOPEPTIDES | HOECHST AKTIENGESELLSCHAFT (DE) | 1997-09-02 | — | — | US | claimed |
| EP-0649426-A1 | INHIBITORS OF RETROVIRAL PROTEASES | HOECHST AKTIENGESELLSCHAFT (DE) | 1995-04-26 | — | — | EP | claimed |
| WO-1994000461-A1 | INHIBITORS OF RETROVIRAL PROTEASES | HOECHST AKTIENGESELLSCHAFT (DE) | 1994-01-06 | — | — | WO | claimed |
| EP-0435059-A1 | Retroviral protease inhibitors | HOECHST AKTIENGESELLSCHAFT (DE) | 1991-07-03 | — | — | EP | claimed |
| EP-0428849-A2 | Retroviral protease inhibitors | HOECHST AKTIENGESELLSCHAFT (DE) | 1991-05-29 | — | — | EP | claimed |
| US-20240083906-A1 | COMPOUNDS AND METHODS FOR INHIBITING MITOTIC PROGRESSION | MILLENNIUM PHARM INC (US) | 2024-03-14 | — | — | US | disclosed |
| US-20220041605-A1 | COMPOUNDS AND METHODS FOR INHIBITING MITOTIC PROGRESSION | MILLENNIUM PHARMACEUTICALS, INC. | 2022-02-10 | — | — | US | disclosed |
| CN-104193750-B | Suppress mitotic Compounds and methods for by suppressing aurora kinase | 千禧药品公司 | 2018-04-27 | — | — | CN | disclosed |
| US-9359327-B2 | Process for the preparation of substituted pyrimidine derivatives | JANSSEN PHARMACEUTICA NV (BE) | 2016-06-07 | — | — | US | disclosed |
| EP-2924035-A1 | SUBSTITUTED PYRIMIDINE DERIVATIVES | Janssen Pharmaceutica NV (BE) | 2015-09-30 | — | — | EP | disclosed |
| EP-2924023-A1 | piperidine und piperazine derivativs | Janssen Pharmaceutica NV (BE) | 2015-09-30 | — | — | EP | disclosed |
| US-9079884-B2 | Process for the preparation of substituted pyrimidine derivatives | JANSSEN PHARMACEUTICA NV (BE) | 2015-07-14 | — | — | US | disclosed |
| EP-0435059-B1 | Retroviral protease inhibitors | HOECHST AG (DE) | 1997-11-05 | — | — | EP | disclosed |
| US-5663139-A | VIRICIDE OLIGOPEPTIDES | HOECHST AKTIENGESELLSCHAFT (DE) | 1997-09-02 | — | — | US | disclosed |
| US-5629431-A | Inhibitors of retroviral proteases | HOECHST AKTIENGESELLSCHAFT (DE) | 1997-05-13 | — | — | US | disclosed |
| EP-0649426-A1 | INHIBITORS OF RETROVIRAL PROTEASES | HOECHST AKTIENGESELLSCHAFT (DE) | 1995-04-26 | — | — | EP | disclosed |
| WO-1994000461-A1 | INHIBITORS OF RETROVIRAL PROTEASES | HOECHST AKTIENGESELLSCHAFT (DE) | 1994-01-06 | — | — | WO | disclosed |
| EP-0435059-A1 | Retroviral protease inhibitors | HOECHST AKTIENGESELLSCHAFT (DE) | 1991-07-03 | — | — | EP | disclosed |
| EP-0428849-A2 | Retroviral protease inhibitors | HOECHST AKTIENGESELLSCHAFT (DE) | 1991-05-29 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220041605-A1 | COMPOUNDS AND METHODS FOR INHIBITING MITOTIC PROGRESSION | AURKC, AURKA, AURKB | BACE1 2861/4885CA12 2704/4885CA1 3017/4885 |
| US-20240083906-A1 | COMPOUNDS AND METHODS FOR INHIBITING MITOTIC PROGRESSION | AURKC, AURKA, AURKB | BACE1 2861/4885CA12 2704/4885CA1 3017/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.